Navigation Links
New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
Date:11/10/2007

ate in the study, patients had to have year-round allergic rhinitis for at least one year and reported sufficiently severe symptoms of nasal stuffiness, discharge and sneezing. Also, all patients had to demonstrate sensitivity to such allergens in their system as shown by a positive skin prick test.

Every morning, caregivers were asked to rate his/her child's symptoms of sneezing, nasal stuffiness, discharge, and itching over the last 24 hours (reflective). Patients' symptoms were also rated at the time immediately before receiving their daily medication (instantaneous).

Over four weeks, patients treated with Nasacort AQ showed a statistically significant (P=0.0328) reduction in the combined symptoms of sneezing, nasal stuffiness, discharge and itching (Total Symptom Score or TSS) measured over the last 24 (-2.31 plus or minus 0.15) compared to placebo (-1.87 plus or minus .151). Immediately before receiving the daily treatment, patients treated with Nasacort AQ also reported a numeric, albeit not statistically significant (P= 0.0946), reduction (-2.28 plus or minus 0.16) in TSS compared to placebo (-1.92 plus or minus .16).

Side effects among patients treated with Nasacort AQ were similar to those given placebo and no serious adverse events or clinically meaningful changes in vital signs were reported in either group. Side effects associated with treatment occurred in 50.8% of patients receiving Nasacort AQ and 48.3% of subjects receiving placebo. The most common treatment-related adverse events during the 4-week of treatment with Nasacort AQ and placebo respectively were cough (7.6%, 9.2%), pyrexia (fever) (6.8%, 8%), headache (5.5%, 4.2%), and nasopharyngitis (nose & throat irritation) (5.1%, 3.8%).

In a subset of the same clinical study, Nasacort AQ showed no significant effect on average adrenal function in children aged 2-5 years with year-round allergic rhinitis

Also presented at ACAAI is a report on the effect of Nasacort AQ on
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. Success of Shape Up Somerville childhood obesity intervention to be presented
5. Survival data presented from phase II study of hormone-resistant prostate cancer patients
6. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
7. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
8. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
9. Horizons AMI trial data to be presented at TCT 2007
10. AMIHOT II trial data presented at TCT
11. Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/17/2014)... 17, 2014 While countless companies tempt patients ... realize the potential dangers of their purchase. Not only is ... a qualified doctor, but patients who buy hCG online are ... there is actually no real hCG present. Illegal internet hCG ... are no safety standards and may contain unknown fillers that ...
(Date:12/17/2014)... December 17, 2014 HeartMath® Inc., ... on stress, heart rate variability (HRV), heart coherence ... its extensive HRV databases and algorithms to chipset ... will enable HeartMath’s partners to offer its HRV ... research, as well as its normative HRV databases ...
(Date:12/17/2014)... 2014 Now in its second year, ... of the best in senior living and home care ... to communities and agencies that have received outstanding online ... the nearly 100,000 providers currently listed on SeniorAdvisor.com, only ... SeniorAdvisor.com Best of 2015 Awards are located all over ...
(Date:12/17/2014)... News) -- Expectant parents should leave prenatal picture-taking to ... Use of ultrasound imaging and heartbeat monitors to ... the agency warns. "Although there is a ... imaging and heartbeat monitors, prudent use of these devices ... an FDA biomedical engineer, said in an agency news ...
Breaking Medicine News(10 mins):Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:FDA Warns Against Fetal 'Keepsake' Videos 2
... March 6 Pregis Corporation, a leading,international ... and specialty packaging solutions, will conduct an ... quarter and full year results on,Thursday, March ... a.m. CT). The call can be,accessed through ...
... 6 Champions,Biotechnology, Inc. (OTC Bulletin Board: CSBR), a ... results.,Full details of the Company,s financial results are available ... For the three months ended January 31, 2008 the ... of $0.02 compared to a net loss,of $37,198 and ...
... EBITDA up 33%, TORONTO, March 6 /PRNewswire-FirstCall/ - ... products and services to the global life,sciences markets, today ... reported net revenues of $296 million, net income of ... $0.14.,Adjusted EBITDA rose to $40 million, up from $30 ...
... Essilor International, the world leader in,ophthalmic optical products, today announced its audited financial results,for the year ended December 31, 2007., ... 2007 2006(2) ... 2,908.1 2,690.0 ... 482.6 + 9.3%, As a % of revenue ...
... The following is a,statement in response to Patrick Swayze ... CEO of the Pancreatic Cancer,Action Network, the only national ... support, community outreach and,advocacy for a cure., "We ... with,pancreatic cancer and our thoughts go out to him ...
... Letter asks Senate Budget Leaders to Reject Oxygen ... Reform Much More Difficult,to Achieve, Letter Draws ... March 5 The Council for Quality,Respiratory Care ... home oxygen,therapy providers and manufacturers who provide care ...
Cached Medicine News:Health News:Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008 2Health News:Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008 3Health News:MDS Reports First Quarter 2008 Results 2Health News:MDS Reports First Quarter 2008 Results 3Health News:MDS Reports First Quarter 2008 Results 4Health News:MDS Reports First Quarter 2008 Results 5Health News:MDS Reports First Quarter 2008 Results 6Health News:MDS Reports First Quarter 2008 Results 7Health News:MDS Reports First Quarter 2008 Results 8Health News:MDS Reports First Quarter 2008 Results 9Health News:MDS Reports First Quarter 2008 Results 10Health News:MDS Reports First Quarter 2008 Results 11Health News:MDS Reports First Quarter 2008 Results 12Health News:MDS Reports First Quarter 2008 Results 13Health News:MDS Reports First Quarter 2008 Results 14Health News:MDS Reports First Quarter 2008 Results 15Health News:MDS Reports First Quarter 2008 Results 16Health News:MDS Reports First Quarter 2008 Results 17Health News:MDS Reports First Quarter 2008 Results 18Health News:MDS Reports First Quarter 2008 Results 19Health News:MDS Reports First Quarter 2008 Results 20Health News:MDS Reports First Quarter 2008 Results 21Health News:MDS Reports First Quarter 2008 Results 22Health News:MDS Reports First Quarter 2008 Results 23Health News:MDS Reports First Quarter 2008 Results 24Health News:MDS Reports First Quarter 2008 Results 25Health News:MDS Reports First Quarter 2008 Results 26Health News:MDS Reports First Quarter 2008 Results 27Health News:MDS Reports First Quarter 2008 Results 28Health News:MDS Reports First Quarter 2008 Results 29Health News:MDS Reports First Quarter 2008 Results 30Health News:MDS Reports First Quarter 2008 Results 31Health News:MDS Reports First Quarter 2008 Results 32Health News:MDS Reports First Quarter 2008 Results 33Health News:Essilor : 2007 Results 2
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced completion of enrollment in its first ... the 3-month observations confirmed the 1-month findings that ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
(Date:12/15/2014)... 15, 2014 BerGenBio AS, a ... drug resistant cancers, today announces that it has raised ... from new and existing investors. BerGenBio will ... development of its pipeline of innovative cancer therapeutics, in ... drug candidate, BGB324, a first-in-class selective Axl kinase inhibitor, ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
... Medtronic Ophthalmics offers the most comprehensive ... Eraser Instruments for Cataract incision, Glaucoma ... discrete coagulation is achieved with minimal ... necrosis. Straight eraser styles are available ...
... offers the most comprehensive family of ... for Cataract incision, Glaucoma filtration, and ... is achieved with minimal tissue trauma ... eraser styles are available in 18, ...
... Medtronic Ophthalmics offers the most comprehensive ... Eraser Instruments for Cataract incision, Glaucoma ... discrete coagulation is achieved with minimal ... necrosis. Straight eraser styles are available ...
Medicine Products: